臺灣博碩士論文加值系統

五爪金英Tithonia diversifolia為菊科(Compositae)植物，為台灣之民間用藥，被用於治療肝病，近年來許多報告已經證實具有保肝、抗發炎及抗腫瘤活性，本實驗室發表一篇有關五爪金英Td-F2萃取物誘導人類肝癌細胞Hep3B細胞週期阻滯及細胞凋亡作用，目前尚無五爪金英抗乳癌的相關研究。
五爪金英Td-F2萃取物，處理MCF-7乳癌細胞24小時細胞毒性試驗(MTT assay)，顯示其IC50為3.589 µg/mL，Tamoxifen為22.368 µg/mL，而五爪金英Td-F2萃取物及Tamoxifen混合藥劑IC50為2.106 µg /mL；經48小時處理細胞，五爪金英Td-F2萃取物其細胞毒性IC50為2.446 µg/mL，Tamoxifen為11.873 µg/mL，而兩種混合藥劑，細胞毒性IC50為1.507 µg/mL，證明五爪金英 Td-F2萃取物對MCF-7乳癌細胞之毒殺作用，具有時間及濃度的依賴性，尤其以五爪金英Td-F2萃取物及Tamoxifen混合藥劑的結果更具有顯著的意義。
顯微鏡觀察，發現MCF-7乳癌細胞外觀型態改變。使用DNA膠體電泳、ELISA kit及自動細胞分析儀測定，結果顯示具有誘導人類乳癌細胞MCF-7凋亡現象。
綜合上述實驗結果，五爪金英Td-F2萃取物具有誘導人類乳癌細胞MCF-7凋亡作用；天然藥物-五爪金英與Tamoxifen合併使用，更具有加乘作用，對於減少乳癌患者長期使用Tamoxifen，導致子宮內膜癌的風險，在未來是可以期許的治療方向。

Tithonia diversifolia, which belongs to Compositae family, is a popular Taiwanese folk medicine, and has traditionally been used for treating liver disease. In recent years, many reports have confirmed that Tithonia diversifolia indeed shows hepatoprotective, anti-inflammatory, and anti-tumor activities. Specifically, our group has shown that Tithonia diversifolia Td-F2 extracts induce cell cycle arrest and apoptosis of Hep3B human hepatoma cells. However, until now there is no anti-breast cancer research on Tithonia diversifolia.
In our experiments, after treating MCF-7 breast cancer cells with Tithonia diversifolia Td-F2 extracts for 24 hours, cytotoxicity test (MTT assay) displayed an IC50 of 3.589 μg/mL, as compared with 22.368 μg/mL and 2.106 μg/mL for those treated with Tamoxifen and the confection of Tithonia diversifolia Td-F2 extract + Tamoxifen , respectively. In addition, by prolonging the treatment time to 48 hours, cytotoxicity test (MTT assay) displayed an IC50 of 2.446 μg/mL, 11.873 μg/mL, and1.507 μg/mL for Tithonia diversifolia Td-F2 extract, Tamoxifen, and the confection of Tithonia diversifolia Td-F2 extract + Tamoxifen, respectively. These results indicate that the toxicity of Tithonia diversifolia Td-F2 extracts shows time and concentration-dependency. The pharmaceutical effectiveness is particularly significant for the confection of Tithonia diversifolia Td-F2 extract + Tamoxifen, among the three splits studied.
In addition, we also performed microscopic observations and confirmed the morphological changes for the appearance of the Tithonia diversifolia Td-F2 extracts-treated MCF-7 breast cancer cells. Finally, all results from DNA gel electrophoresis, ELISA kit, and automatic cell analyzer confirmed that Tithonia diversifolia Td-F2 extracts indeed induce cell apoptosis.
In summary, Tithonia diversifolia Td-F2 extracts show significant toxic effects and induce apoptosis in MCF-7 human breast cancer cells. The toxic effects are especially significant synergistic by confection Tithonia diversifolia Td-F2 extracts with Tamoxifen. The confection therefore appears to be very promising for reducing the risk of uterine cancer in conventional adjuvant therapy using pure Tamoxifen, and is a potential cancer chemo-preventive agent.

圖目次 VII
第壹章 緒論 1
第一節 乳癌簡介 1
一、乳癌 1
二、臨床治療方式 4
三、乳癌的敏感性基因 5
第二節 細胞週期 7
一、細胞週期(cell cycle)簡介 7
二、細胞週期的調控 8
第三節 細胞凋亡 16
一、細胞凋亡 (apoptosis) 簡介 16
二、細胞凋亡路徑 (apoptosis pathways) 簡介 18
第四節 抗癌機轉 20
第貳章 研究目的 24
第参章 材料與方法 25
第一節 實驗材料 25
一、實驗藥品及試劑 25
二、儀器和設備 26
一、細胞培養 (Cell culture) 28
二、細胞型態觀察 (cell morphology) 28
三、細胞毒性試驗 (MTT assay) 28
四、DNA 片段化分析 (DNA ladder) 29
五、細胞凋亡免疫酵素分析法(Apoptosis ELISA Assay) 30
六、自動細胞分析儀 (Next generation cell analysis) 31
第肆章 結果與討論 35
第伍章 結論 55
第陸章 参考文獻 58

Aaronson, SA. (1991). Growth factors and cancer. Science, 254(5035), 1146-1153. doi: 10.1126/science.1659742
Antoniou, Anthony, Pharoah, PDP, Narod, Steven, Risch, Harvey A, Eyfjord, Jorunn E, Hopper, JL, . . . Borg, Åke. (2003). Average Risks of Breast and Ovarian Cancer Associated with< i> BRCA1 or< i> BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. The American Journal of Human Genetics, 72(5), 1117-1130.
Bartek, J., Iggo, R., Gannon, J., &; Lane, D. P. (1990). Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5(6), 893-899.
Baum, M., Buzdar, A., Cuzick, J., Forbes, J., Houghton, J., Howell, A., . . . null. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 98(9), 1802-1810.
Belgareh, N., Rabut, G., Bai, S. W., van Overbeek, M., Beaudouin, J., Daigle, N., . . . Doye, V. (2001). An evolutionarily conserved NPC subcomplex, which redistributes in part to kinetochores in mammalian cells. J Cell Biol, 154(6), 1147-1160. doi: 10.1083/jcb.200101081
Boatright, Kelly M., &; Salvesen, Guy S. (2003). Mechanisms of caspase activation. Current Opinion in Cell Biology, 15(6), 725-731. doi: http://dx.doi.org/10.1016/j.ceb.2003.10.009
Brown, M. A., &; Solomon, E. (1994). Towards cloning the familial breast-ovarian cancer gene on chromosome 17. Curr Opin Genet Dev, 4(3), 439-445.
Cattoretti, Giorgio, Rilke, Franco, Andreola, Salvatore, D'Amato, Lucia, &; Delia, Domenico. (1988). P53 expression in breast cancer. International Journal of Cancer, 41(2), 178-183. doi: 10.1002/ijc.2910410204
Claus, Elizabeth B., Schildkraut, Joellen M., Thompson, W. Douglas, &; Risch, Neil J. (1996). The genetic attributable risk of breast and ovarian cancer. Cancer, 77(11), 2318-2324. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z
Colditz, G. A., Willett, W. C., Hunter, D. J., &; et al. (1993). Family history, age, and risk of breast cancer: Prospective data from the nurses' health study. JAMA, 270(3), 338-343. doi: 10.1001/jama.1993.03510030062035
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., &; Boyle, P. (2003). Overview of the main outcomes in breast-cancer prevention trials. The Lancet, 361(9354), 296-300. doi: http://dx.doi.org/10.1016/S0140-6736(03)12342-2
Di Leonardo, A., Linke, S. P., Clarkin, K., &; Wahl, G. M. (1994). DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev, 8(21), 2540-2551.
Earnshaw, W. C., &; Cooke, C. A. (1991). Analysis of the distribution of the INCENPs throughout mitosis reveals the existence of a pathway of structural changes in the chromosomes during metaphase and early events in cleavage furrow formation. J Cell Sci, 98 ( Pt 4), 443-461.
Eifel, P., Axelson, J. A., Costa, J., Crowley, J., Curran, W. J., Deshler, A., . . . Roter, D. (2001). National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. Journal of the National Cancer Institute, 93(13), 979-989.
Eimon, P. M., Kratz, E., Varfolomeev, E., Hymowitz, S. G., Stern, H., Zha, J., &; Ashkenazi, A. (2006). Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ, 13(10), 1619-1630. doi: 10.1038/sj.cdd.4402015
Eliyahu, Daniel, Michalovitz, Dan, Eliyahu, Siona, Pinhasi-Kimhi, Orit, &; Oren, Moshe. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National Academy of Sciences, 86(22), 8763-8767.
Elledge, Stephen J. (1996). Cell Cycle Checkpoints: Preventing an Identity Crisis. Science, 274(5293), 1664-1672. doi: 10.1126/science.274.5293.1664
Fakhoury, Isabelle, &; Gali-Muhtasib, Hala. (2011). Salograviolide A: a plant-derived sesquiterpene lactone with promising anti-inflammatory and anticancer effects. Advances in cancer therapy. InTech Publishing Group, Croatia, 369-388.
Finlay, Cathy A., Hinds, Philip W., &; Levine, Arnold J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57(7), 1083-1093. doi: http://dx.doi.org/10.1016/0092-8674(89)90045-7
Fisher, Bernard, Bauer, Madeline, Margolese, Richard, Poisson, Roger, Pilch, Yosef, Redmond, Carol, . . . Russell, Ian. (1985). Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer. New England Journal of Medicine, 312(11), 665-673. doi: doi:10.1056/NEJM198503143121101
Fisher, Bernard, Redmond, Carol, Poisson, Roger, Margolese, Richard, Wolmark, Norman, Wickerham, Lawrence, . . . Sidorovich, Lynne. (1989). Eight-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Lumpectomy with or without Irradiation in the Treatment of Breast Cancer. New England Journal of Medicine, 320(13), 822-828. doi: doi:10.1056/NEJM198903303201302
Fisher, Edwin R., Sass, Richard, Fisher, Bernard, Wickerham, Lawrence, Paik, S. M., &; Collaborating Nsabp, Investigators. (1986). Pathologic findings from the national surgical adjuvant breast project (protocol 6) I. Intraductal carcinoma (DCIS). Cancer, 57(2), 197-208. doi: 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N
Giancotti, Filippo G., &; Ruoslahti, Erkki. (1999). Integrin Signaling. Science, 285(5430), 1028-1033. doi: 10.1126/science.285.5430.1028
Giménez-Martín, G., González-Fernández, A., &; Lopez-Sáez, J. F. (1966). Duration of the division cycle in diploid, binucleate and tetraploid cells. Experimental Cell Research, 43(2), 293-300. doi: http://dx.doi.org/10.1016/0014-4827(66)90056-5
Greenwald, Peter, Nasca, Philip C., Lawrence, Charles E., Horton, John, McGarrah, Robert P., Gabriele, Thomas, &; Carlton, Kathleen. (1978). Estimated Effect of Breast Self-Examination and Routine Physician Examinations on Breast-Cancer Mortality. New England Journal of Medicine, 299(6), 271-273. doi: doi:10.1056/NEJM197808102990602
Hatakeyama, Masanori, &; Weinberg, RobertA. (1995). The role of RB in cell cycle control. In L. Meijer, S. Guidet &; H. Y. L. Tung (Eds.), Progress in Cell Cycle Research (pp. 9-19): Springer US.
Hench, Larry L., &; Polak, Julia M. (2002). Third-Generation Biomedical Materials. Science, 295(5557), 1014-1017. doi: 10.1126/science.1067404
Herrera, R E, Sah, V P, Williams, B O, Mäkelä, T P, Weinberg, R A, &; Jacks, T. (1996). Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Molecular and Cellular Biology, 16(5), 2402-2407.
Holmes, Frankie Ann, Walters, Ronald S., Theriault, Richard L., Buzdar, Aman U., Frye, Debra K., Hortobagyi, Gabriel N., . . . Raber, Martin N. (1991). Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer. Journal of the National Cancer Institute, 83(24), 1797-1805. doi: 10.1093/jnci/83.24.1797
Hoskins, Kent F, Stopfer, Jill E, Calzone, Kathleen A, Merajver, Sofia D, Rebbeck, Timothy R, Garber, Judy E, &; Weber, Barbara L. (1995). Assessment and counseling for women with a family history of breast cancer. JAMA: the journal of the American Medical Association, 273(7), 577-585.
Hunter, Tony, &; Pines, Jonathan. (1994). Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79(4), 573-582.
Isaacs, William B., Carter, Bob S., &; Ewing, Charles M. (1991). Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles. Cancer Research, 51(17), 4716-4720.
Javelaud, Delphine, &; Besançon, Françoise. (2002). Inactivation of p21 WAF1 Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio. Journal of Biological Chemistry, 277(40), 37949-37954. doi: 10.1074/jbc.M204497200
Kelsey, J. L., Gammon, M. D., &; John, E. M. (1993). Reproductive factors and breast cancer. Epidemiol Rev, 15(1), 36-47.
Kerr, J. F. R. (1971). Shrinkage necrosis: A distinct mode of cellular death. The Journal of Pathology, 105(1), 13-20. doi: 10.1002/path.1711050103
Kerr, J. F., Wyllie, A. H., &; Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 26(4), 239-257.
Khanna, K. K., Keating, K. E., Kozlov, S., Scott, S., Gatei, M., Hobson, K., . . . Lavin, M. F. (1998). ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet, 20(4), 398-400. doi: 10.1038/3882
Knoblich, J. A., &; Lehner, C. F. (1993). Synergistic action of Drosophila cyclins A and B during the G2-M transition. EMBO J, 12(1), 65-74.
Kroemer, G., Dallaporta, B., &; Resche-Rigon, M. (1998). The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol, 60, 619-642. doi: 10.1146/annurev.physiol.60.1.619
Lee, M. G., Norbury, C. J., Spurr, N. K., &; Nurse, P. (1988). Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein. Nature, 333(6174), 676-679. doi: 10.1038/333676a0
Leitch, A. Marilyn, Dodd, Gerald D., Costanza, Mary, Linver, Michael, Pressman, Peter, McGinnis, LaMar, &; Smith, Robert A. (1997). American Cancer Society guidelines for the early detection of breast cancer: Update 1997. CA: A Cancer Journal for Clinicians, 47(3), 150-153. doi: 10.3322/canjclin.47.3.150
Levine, A. J., Momand, J., &; Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature, 351(6326), 453-456.
Majno, G., &; Joris, I. (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol, 146(1), 3-15.
Malumbres, Marcos, &; Barbacid, Mariano. (2005). Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 30(11), 630-641. doi: http://dx.doi.org/10.1016/j.tibs.2005.09.005
March, David E., Wechsler, Richard J., Kurtz, Alfred B., Rosenberg, Anne L., &; Needleman, Laurence. (1991). CT-Pathologic Correlation of Axillary Lymph Nodes in Breast Carcinoma. Journal of Computer Assisted Tomography, 15(3), 440-444.
McDermott, F. (1991). Risk factors in breast cancer. Aust Fam Physician, 20(10), 1455-1460.
Meijer, Laurent, Borgne, Annie, Mulner, Odile, Chong, James P. J., Blow, J. Julian, Inagaki, Naoyuki, . . . Moulinoux, Jacques-Philippe. (1997). Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5. European Journal of Biochemistry, 243(1-2), 527-536. doi: 10.1111/j.1432-1033.1997.t01-2-00527.x
Meijers-Heijboer, Hanne, van Geel, Bert, van Putten, Wim L.J., Henzen-Logmans, Sonja C., Seynaeve, Caroline, Menke-Pluymers, Marian B.E., . . . Klijn, Jan G.M. (2001). Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation. New England Journal of Medicine, 345(3), 159-164. doi: doi:10.1056/NEJM200107193450301
Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol, 13, 261-291. doi: 10.1146/annurev.cellbio.13.1.261

Morimoto, Libby M, White, Emily, Chen, Z, Chlebowski, Rowan T, Hays, Jennifer, Kuller, Lewis, . . . Muti, Paola C. (2002). Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes &; Control, 13(8), 741-751.
Morris, L., Allen, K. E., &; La Thangue, N. B. (2000). Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nat Cell Biol, 2(4), 232-239. doi: 10.1038/35008660
Nevins. (1992). E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science, 258(5081), 424-429. doi: 10.1126/science.1411535
Nigg, Erich A. (1995). Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. BioEssays, 17(6), 471-480. doi: 10.1002/bies.950170603
Nigro, Janice M, Baker, Suzanne J, Preisinger, Antonette C, Jessup, J Milburn, Hosteller, Richard, Cleary, Karen, . . . Devilee, Peter. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature, 342(6250), 705-708.
Padmakumar, V. C., Aleem, E., Berthet, C., Hilton, M. B., &; Kaldis, P. (2009). Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Mol Cell Biol, 29(10), 2582-2593. doi: 10.1128/mcb.00952-08
Patel, T, Gores, G J, &; Kaufmann, S H. (1996). The role of proteases during apoptosis. The FASEB Journal, 10(5), 587-597.
Pike, M. C., Spicer, D. V., Dahmoush, L., &; Press, M. F. (1993). Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev, 15(1), 17-35.
Pollard, Thomas D, &; Cooper, John A. (1986). Actin and actin-binding proteins. A critical evaluation of mechanisms and functions. Annual review of biochemistry, 55(1), 987-1035.
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van 't Veer, L., Garber, J. E., . . . Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 22(6), 1055-1062. doi: 10.1200/JCO.2004.04.188
Resnitzky, D., Gossen, M., Bujard, H., &; Reed, S. I. (1994). Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol, 14(3), 1669-1679.
Robinow, C. F. (1963). Observations on cell growth, mitosis, and division in the fungus Basidiobolus ranarum. J Cell Biol, 17, 123-152.
Samuilov, V. D., Oleskin, A. V., &; Lagunova, E. M. (2000). Programmed cell death. Biochemistry. Biokhimiia, 65(8), 873-887.
Sgroi, D. C., Teng, S., Robinson, G., LeVangie, R., Hudson, J. R., Jr., &; Elkahloun, A. G. (1999). In vivo gene expression profile analysis of human breast cancer progression. Cancer Res, 59(22), 5656-5661.
Shyamala, G., Chou, Y. C., Louie, S. G., Guzman, R. C., Smith, G. H., &; Nandi, S. (2002). Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. The Journal of Steroid Biochemistry and Molecular Biology, 80(2), 137-148. doi: http://dx.doi.org/10.1016/S0960-0760(01)00182-0
Siegel, R., Naishadham, D., &; Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J Clin, 62(1), 10-29. doi: 10.3322/caac.20138
Smith-Warner, S. A., Spiegelman, D., Yaun, S., &; et al. (1998). Alcohol and breast cancer in women: A pooled analysis of cohort studies. JAMA, 279(7), 535-540. doi: 10.1001/jama.279.7.535
Spierings, Diana, McStay, Gavin, Saleh, Maya, Bender, Cheryl, Chipuk, Jerry, Maurer, Uli, &; Green, Douglas R. (2005). Connected to Death: The (Unexpurgated) Mitochondrial Pathway of Apoptosis. Science, 310(5745), 66-67. doi: 10.1126/science.1117105
Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., . . . Stratton, M. R. (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature, 486(7403), 400-404. doi: 10.1038/nature11017
Struewing, Jeffery P, Hartge, Patricia, Wacholder, Sholom, Baker, Sonya M, Berlin, Martha, McAdams, Mary, . . . Tucker, Margaret A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine, 336(20), 1401-1408.
Takahashi, Manabu. (1966). Theoretical basis for cell cycle analysis I. Labelled mitosis wave method. Journal of Theoretical Biology, 13(0), 202-211. doi: http://dx.doi.org/10.1016/0022-5193(66)90017-8
Torok, Natalie J, &; Gores, Gregory J. (2005). Apoptosis of biliary epithelial cells. Eurekah Bioscience, 1(1), 59-63.
Wade Harper, J., Adami, Guy R., Wei, Nan, Keyomarsi, Khandan, &; Elledge, Stephen J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75(4), 805-816. doi: http://dx.doi.org/10.1016/0092-8674(93)90499-G
Walsh, T., Casadei, S., Coats, K., &; et al. (2006). SPectrum of mutations in brca1, brca2, chek2, and tp53 in families at high risk of breast cancer. JAMA, 295(12), 1379-1388. doi: 10.1001/jama.295.12.1379
Westphal, C. H., Schmaltz, C., Rowan, S., Elson, A., Fisher, D. E., &; Leder, P. (1997). Genetic interactions between atm and p53 influence cellular proliferation and irradiation-induced cell cycle checkpoints. Cancer Res, 57(9), 1664-1667.
Westphal, Christoph Heiner. (1997). Cell-cycle signaling: Atm displays its many talents. Current Biology, 7(12), R789-R792. doi: http://dx.doi.org/10.1016/S0960-9822(06)00406-4
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., . . . et al. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 265(5181), 2088-2090.
Yon, J. H., Daniel-Johnson, J., Carter, L. B., &; Jevtovic-Todorovic, V. (2005). Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. Neuroscience, 135(3), 815-827. doi: http://dx.doi.org/10.1016/j.neuroscience.2005.03.064
Zindy, Frédérique, Lamas, Eugénia, Chenivesse, Xavier, Sobczak, Joëlle, Wang, Jian, Fesquet, Didier, . . . Bréchot, Christian. (1992). Cyclin A is required in S phase in normal epithelial cells. Biochemical and Biophysical Research Communications, 182(3), 1144-1154. doi: http://dx.doi.org/10.1016/0006-291X(92)91851-G
Ziyaie, D., Hupp, T. R., &; Thompson, A. M. (2000). p53 and breast cancer. The Breast, 9(5), 239-246. doi: http://dx.doi.org/10.1054/brst.2000.0199
周林世珍, 廖保鑫, 李天翎, 楊世煌, &; 周明勇. (2005). Regulation of Heat Shock-induced p53 Signaling in OC2 Human Oral Cancer Cells. [熱緊迫誘發人類口腔癌細胞p53訊息傅導之調節]. 中山醫學雜誌, 16(2), 209-224.
林俊清, 林敏玲, &; 楊政哲. (1992). 五爪金英之生藥學研究. [The Pharmacognostical Studies on "Wuu-Joa-Jin-Ing"]. 中醫藥雜誌, 3(2), 61-71.
廖繼鼎. (2010). 臨床腫瘤學: 合記圖書發行.
盧泯任, 李孟修, 陳錫金, 吳裕仁, &; 黃瑞齡. (2011). 五爪金英Td-F2萃取物誘導人類肝癌細胞Hep3B細胞週期阻滯及細胞凋亡作用. [A Td-F2 Extract from Tithonia Diversifolia Induced Cell Cycle Arrest and Apoptosis on Hep3B Human Hepatoma Cells]. 美和學報, 31(1), 15-33.